Drug intelligence / Profile preview

TNC-1

Development stage: Preclinical
Modality: Small Molecules
Administration: Topical, Intracameral Injection

Overview

TNC-1 is a novel triazole near-infrared (NIR) cyanine dye developed for in-vivo fluorescent imaging. It is designed to detect and characterize activated T-cell activity, particularly within the eye, and has shown greater fluorescence intensity compared to Indocyanine green (ICG) without exhibiting ocular cell toxicity at working concentrations. Its uptake into CD4+T-cells is mediated by dynamin-dependent processes, suggesting its potential as a diagnostic marker for ocular inflammatory diseases.

Other names: Triazole NIR cyanine dye

Targets

CD4 (T lymphocyte surface antigen)

Beyond the preview

Go deeper on TNC-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TNC-1.

Explore the full profile